Analyst Price Target is $6.00
▲ +176.50% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 176.50% upside from the last price of $2.17.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Cardiol Therapeutics. This Buy consensus rating has held steady for over two years.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Read More